Wednesday, October 14, 2026

Wayfair Stock Was Up By 10.14% Today

ViaNews Editorial Team

February 15, 2023

Wayfair Stock Was Up By 10.14%  Today

(VIANEWS) - The NYSE ended the session with Wayfair jumping 10.14% to $55.48 on Wednesday, after two consecutive sessions in a row of losses. NYSE dropped 0.19% to $15,994.78, following the last session's downward trend on what was a somewhat bearish trend exchanging session today.

Wayfair's last close was $50.37, 83.1% under its 52-week high of $298.00.

About Wayfair

Wayfair Inc. engages in the e-commerce business in the United States and internationally. The company provides approximately thirty-three million products for the home sector under various brands. It offers online selections of furniture, décor, housewares, and home improvement products through its sites, including Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold brands. The company was founded in 2002 and is headquartered in Boston, Massachusetts.

Earnings Per Share

As for profitability, Wayfair has a trailing twelve months EPS of $1.86.

PE Ratio

Wayfair has a trailing twelve months price to earnings ratio of 29.83. Meaning, the purchaser of the share is investing $29.83 for every dollar of annual earnings.

Sales Growth

Wayfair's sales growth for the next quarter is 3.4%.

Volume

Today's last reported volume for Wayfair is 4394360 which is 20.83% below its average volume of 5551100.

Growth Estimates Quarters

The company's growth estimates for the current quarter and the next is a negative 196.8% and a negative 1200%, respectively.

More news about Wayfair (W).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com